Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Finke

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Biochemistry|February 13, 2003
Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocketLaurie A Castonguay, Youmin Weng, William Adolfsen, et al.
Neuropharmacology|March 23, 2000
The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferretsF D Tattersall, W Rycroft, M Cumberbatch, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanesP E Finke, B Oates, S G Mills, et al.
ACS Medicinal Chemistry Letters|November 16, 2018
Optimization of Preclinical Metabolism for Somatostatin Receptor Subtype 5-Selective AntagonistsWeiguo Liu, Zahid Hussain, Yi Zang, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonistsChristopher W Plummer, Paul E Finke, Sander G Mills, et al.
Journal of Medicinal Chemistry|November 7, 1998
Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonistJ J Hale, S G Mills, M MacCoss, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2004
The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogsSu-Er W Huskey, Brian J Dean, George A Doss, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activityJ J Hale, R J Budhu, E B Holson, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanesP E Finke, L C Meurer, B Oates, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonistsLaura C Meurer, Paul E Finke, Sander G Mills, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Biochemistry|February 13, 2003
Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocketLaurie A Castonguay, Youmin Weng, William Adolfsen, et al.
Neuropharmacology|March 23, 2000
The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferretsF D Tattersall, W Rycroft, M Cumberbatch, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanesP E Finke, B Oates, S G Mills, et al.
ACS Medicinal Chemistry Letters|November 16, 2018
Optimization of Preclinical Metabolism for Somatostatin Receptor Subtype 5-Selective AntagonistsWeiguo Liu, Zahid Hussain, Yi Zang, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonistsChristopher W Plummer, Paul E Finke, Sander G Mills, et al.
Journal of Medicinal Chemistry|November 7, 1998
Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonistJ J Hale, S G Mills, M MacCoss, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2004
The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogsSu-Er W Huskey, Brian J Dean, George A Doss, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activityJ J Hale, R J Budhu, E B Holson, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanesP E Finke, L C Meurer, B Oates, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonistsLaura C Meurer, Paul E Finke, Sander G Mills, et al.
Pageof 7